← Back to Search

Arginase Inhibitor

Cohort 2 for Cystic Fibrosis

Phase 1
Waitlist Available
Research Sponsored by Calithera Biosciences, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial is testing a new drug to treat cystic fibrosis. The goal is to find out if it is safe and tolerated by people with the disease.

Eligible Conditions
  • Cystic Fibrosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

5Treatment groups
Experimental Treatment
Placebo Group
Group I: Cohort 4Experimental Treatment1 Intervention
CB-280 twice daily at 400 mg for 14 days
Group II: Cohort 3Experimental Treatment1 Intervention
CB-280 twice daily at 200 mg for 14 days
Group III: Cohort 2Experimental Treatment1 Intervention
CB-280 twice daily at 100 mg for 14 days
Group IV: Cohort 1Experimental Treatment1 Intervention
CB-280 twice daily at 50 mg for 14 days
Group V: PlaceboPlacebo Group1 Intervention
Placebo twice daily for 14 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CB-280
2020
Completed Phase 1
~40

Find a Location

Who is running the clinical trial?

Calithera Biosciences, IncLead Sponsor
33 Previous Clinical Trials
1,989 Total Patients Enrolled
Emil T Kuriakose, MDStudy DirectorCalithera Bioscience
~6 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top